You are entering webpages belonging to the American Association of Orthopaedic Surgeons, which includes information and resources for Association advocacy efforts and the Political Action Committee of The American Association of Orthopaedic Surgeons (OrthoPAC).
To ensure that medical treatments reach patients in a timely manner, the AAOS closely follows Food and Drug Administration (FDA) regulatory and legislative developments and provides appropriate responses to proposed rules, guidance documents, and legislative initiatives. AAOS supports the approval and clearance of safe and effective medical products for musculoskeletal care. Additionally, with appropriate data, AAOS encourages the downclassification of devices whose risk/benefit profile can be managed with the FDA's use of general and special controls, including the use of guidance documents and consensus standards.
Also note, to help prepare our members for conversations with their patients, AAOS launched a pain alleviation tool kit. The online resource includes pre- and postoperative discussion talking points on pain relief, common pain relief solutions, orthopaedic and emergency department opioid strategies, a questionnaire for determining patient opioid addiction risk, and safe use storage and disposal strategies/resources.
Position Statements
-
Safe and Effective Alleviation of Pain and Optimal Opioid Stewardship
-
Value Driven Use of Orthopaedic Implants Position Statement
-
Physician Directed Use of Medical Products
-
Use of Musculoskeletal Tissue Allografts Information Statement
-
Cell-and Tissue-Engineered Products Information Statement
-
Consensus Standards for Medical Devices Position Statement
-
Implant Device Recalls Information Statement
-
Pharmaceutical and Device Company Direct-to-Consumer Advertising Position Statement
Important Resources
Comment/Congressional Letters
-
AAOS Manufacturer Disclosure Initiative Letter.pdf
-
AAOS Comments – CDC Proposed Opioid Guidelines 2022
-
AAOS Letter of Support - Medical Controlled Substances Transportation Act
-
AAOS Comments on FDA Quality System Regulations
-
AAOS Comments on CDC Proposed Opioid Guidelines 2022
-
AAOS Letter to the FDA on Biologics Regulation
-
AAOS Comments on MCIT Pathway Proposed Rule
-
AAOS to CMS on Opioid Addiction Prevention Action Plan
-
AAOS Comments on IPI Model for Medicare Part B
-
AAOS Comments on DMEPOS Competitive Bidding Program
-
AAOS Letter to House Energy and Commerce Committee re: Opioids
-
AAOS Letter to Senate HELP Committee re: Opioids
-
AAOS Letter to FDA on Prescribing Intervention
-
AAOS Letter to House Ways and Means Committee re: Opioids
-
AAOS Letter to CMS on Drug Utilization Review Controls
-
AAOS Letter to Senate Finance Committee re: Opioids